Children with an extremely rare form of systemic scleroderma tend to experience longer diagnostic delays, are more likely to have heart involvement, and have worse clinical outcomes, according to a study of five children with the condition, which has no skin involvement. The study, “Systemic sclerosis…
News
Platelet inhibitors, or anti-platelet medication, is associated with a lower occurrence of digital ulcers — open sores on the fingers or toes — in people with systemic sclerosis (SSc), a study shows. These findings may “assist rheumatologists in decision making regarding the use of platelet inhibitors in SSc patients…
Black patients with scleroderma are at higher risk of mortality and serious complications such as interstitial lung disease than those of other racial or ethnic groups, a single-center U.S. study found. These findings may foster early monitoring of these patients as well as greater awareness among clinicians, researchers…
Infection was the leading cause of acute hospitalization and mortality in people with systemic sclerosis (SSc), a 10-year hospital study in Portugal found. Although most infection-related hospital admissions occurred in those with underlying lung disease, the scientists noted that a decrease in the total number of hospitalizations during the…
Ofev (nintedanib) effectively slowed lung function decline in adults with interstitial lung disease (ILD) associated with systemic sclerosis (SSc-ILD) across patient groups based on autoantibody status and skin involvement severity, according to an analysis of the SENSCIS trial. These findings add to the trial’s top-line results,…
Cudetaxestat, a potential anti-scarring medication, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of scleroderma. “There are limited options and high medical need for patients suffering from systemic sclerosis [SSc, or scleroderma],” Daven Mody, vice president of regulatory affairs…
A celebrity lineup is slated for an upcoming fundraiser by the Scleroderma Research Foundation (SRF) to support disease research. The Cool Comedy, Hot Cuisine event will be livestreamed on Sunday, Oct. 17, at 5 pm PDT or 8 pm EDT. Tickets, starting at $100, can be purchased…
Bionews Insights is launching a new survey, in collaboration with Scleroderma News, with the goal of understanding how different aspects of disease affect an individual’s quality of life. The survey, which is expected to take approximately 15 minutes to complete, will use the WHOQOL-100 questions, developed by the World…
Most scleroderma patients who responded to a U.S.-based online survey report being satisfied with their current medications and are not considering switching treatments. However, only about half of survey respondents reported being satisfied with their overall life quality, or optimistic about the future, perhaps highlighting gaps in care for…
Chemomab Therapeutics is teaming up with the University of Leeds to investigate the role of the protein CCL24 in scleroderma (SSc) — particularly how it contributes to blood vessel damage. Their findings may aid in the clinical development of CM-101, Chemomab’s first-in-class antibody designed to target and…
Recent Posts
- Abnormal fatty acid metabolism may play role in scleroderma: Analysis
- Cosmetic laser therapy could be repurposed for localized scleroderma
- Antibody levels may help reflect quality of life in people with scleroderma
- Certain antibodies tied to poorer outcomes in systemic sclerosis
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy
- Combination drug therapy boosts lung, skin health in SSc patients
- On choosing medicine’s side effects over scleroderma progression
- Telerehabilitation improves hand mobility in scleroderma women
- Molecular pathway ID’d as key driver of scarring in scleroderma